RVMD
Revolution Medicines, Inc.
Biotechnology
Market Cap$32.12B
5Y Perf.+427.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RVMD vs NUVL
Revenue, margins, valuation, and 5-year total return — side by side.
NUVL
Nuvalent, Inc.
Biotechnology
Market Cap$6.92B
5Y Perf.+471.3%
RVMD vs NUVL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RVMD | NUVL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $32.12B | $6.92B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-1.37B | $-381M |
| Total Debt | $159M | $0.00 |
| Cash & Equiv. | $384M | $146M |
RVMD vs NUVL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RVMD
NUVL
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Revolution Medicine… (RVMD) | 100 | 527.5 | +427.5% |
| Nuvalent, Inc. (NUVL) | 100 | 571.3 | +471.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RVMD vs NUVL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NUVL leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Revolution Medicines, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
RVMD
Revolution Medicines, Inc.
The Income Pick
RVMD is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.08
- EPS growth -66.2%
- Lower volatility, beta 1.08, Low D/E 9.7%, current ratio 7.14x
Best for: income & stability and growth exposure
NUVL
Nuvalent, Inc.
The Long-Run Compounder
NUVL carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 456.1% 10Y total return vs RVMD's 422.7%
- 38.2% revenue growth vs RVMD's -98.6%
- 3.4% margin vs RVMD's 2.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVL | 38.2% revenue growth vs RVMD's -98.6% |
| Quality / Margins | NUVL | 3.4% margin vs RVMD's 2.8% |
| Stability / Safety | RVMD | Beta 1.08 vs NUVL's 1.09 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RVMD | +303.5% vs NUVL's +52.9% |
| Efficiency (ROA) | NUVL | -38.9% ROA vs RVMD's -59.1%, ROIC -32.6% vs -54.3% |
RVMD vs NUVL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
Segment breakdown not available.
RVMD vs NUVL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNUVLLAGGINGRVMD
RVMDRevolution Medicines,…
2leads
NUVLNuvalent, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs RVMDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NUVL1/1
Valuation MetricsMultiples, price ratios, and targets
NUVL2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NUVL5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
RVMD4/6
Risk & VolatilityBeta, volatility, and downside exposure
RVMD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NUVL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RVMD and NUVL operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | RVMDRevolution Medici… | NUVLNuvalent, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$1.4B | -$408M |
| Net IncomeAfter-tax profit | -$1.4B | -$381M |
| Free Cash FlowCash after capex | -$1.1B | -$264M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -102.7% | -32.8% |
NUVL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
NUVL leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | RVMDRevolution Medici… | NUVLNuvalent, Inc. |
|---|---|---|
| Market CapShares × price | $32.1B | $6.9B |
| Enterprise ValueMkt cap + debt − cash | $31.9B | $6.8B |
| Trailing P/EPrice ÷ TTM EPS | -25.39x | -26.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 17.61x | 6.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
NUVL leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
NUVL leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
NUVL delivers a -45.1% return on equity — every $100 of shareholder capital generates $-45 in annual profit, vs $-83 for RVMD.
| Metric | RVMDRevolution Medici… | NUVLNuvalent, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -83.2% | -45.1% |
| ROA (TTM)Return on assets | -59.1% | -38.9% |
| ROICReturn on invested capital | -54.3% | -32.6% |
| ROCEReturn on capital employed | -53.0% | -31.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | 0.10x | — |
| Net DebtTotal debt minus cash | -$225M | -$146M |
| Cash & Equiv.Liquid assets | $384M | $146M |
| Total DebtShort + long-term debt | $159M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -81.62x | — |
NUVL leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
RVMD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVL five years ago would be worth $55,605 today (with dividends reinvested), compared to $52,093 for RVMD. Over the past 12 months, RVMD leads with a +303.5% total return vs NUVL's +52.9%. The 3-year compound annual growth rate (CAGR) favors RVMD at 83.5% vs NUVL's 40.3% — a key indicator of consistent wealth creation.
| Metric | RVMDRevolution Medici… | NUVLNuvalent, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +91.2% | +3.4% |
| 1-Year ReturnPast 12 months | +303.5% | +52.9% |
| 3-Year ReturnCumulative with dividends | +518.1% | +176.1% |
| 5-Year ReturnCumulative with dividends | +420.9% | +456.1% |
| 10-Year ReturnCumulative with dividends | +422.7% | +456.1% |
| CAGR (3Y)Annualised 3-year return | +83.5% | +40.3% |
RVMD leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
RVMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RVMD is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than NUVL's 1.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 97.0% from its 52-week high vs NUVL's 92.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RVMDRevolution Medici… | NUVLNuvalent, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 1.09x |
| 52-Week HighHighest price in past year | $155.70 | $113.02 |
| 52-Week LowLowest price in past year | $34.00 | $63.56 |
| % of 52W HighCurrent price vs 52-week peak | +97.0% | +92.3% |
| RSI (14)Momentum oscillator 0–100 | 64.2 | 46.9 |
| Avg Volume (50D)Average daily shares traded | 3.0M | 539K |
RVMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RVMD as "Buy" and NUVL as "Buy". Consensus price targets imply 38.5% upside for NUVL (target: $144) vs 2.5% for RVMD (target: $155).
| Metric | RVMDRevolution Medici… | NUVLNuvalent, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $154.80 | $144.40 |
| # AnalystsCovering analysts | 22 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NUVL leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). RVMD leads in 2 (Total Returns, Risk & Volatility).
Best OverallNuvalent, Inc. (NUVL)Leads 3 of 6 categories
Loading custom metrics...
RVMD vs NUVL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RVMD or NUVL a better buy right now?
Analysts rate Revolution Medicines, Inc.
(RVMD) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RVMD or NUVL?
Over the past 5 years, Nuvalent, Inc.
(NUVL) delivered a total return of +456. 1%, compared to +420. 9% for Revolution Medicines, Inc. (RVMD). Over 10 years, the gap is even starker: NUVL returned +456. 1% versus RVMD's +422. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RVMD or NUVL?
By beta (market sensitivity over 5 years), Revolution Medicines, Inc.
(RVMD) is the lower-risk stock at 1. 08β versus Nuvalent, Inc. 's 1. 09β — meaning NUVL is approximately 1% more volatile than RVMD relative to the S&P 500.
04Which is growing faster — RVMD or NUVL?
On earnings-per-share growth, the picture is similar: Revolution Medicines, Inc.
grew EPS -66. 2% year-over-year, compared to -81. 1% for Nuvalent, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RVMD or NUVL?
Revolution Medicines, Inc.
(RVMD) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Nuvalent, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RVMD leads at 0. 0% versus 0. 0% for NUVL. At the gross margin level — before operating expenses — RVMD leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RVMD or NUVL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RVMD or NUVL better for a retirement portfolio?
For long-horizon retirement investors, Nuvalent, Inc.
(NUVL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09), +456. 1% 10Y return). Both have compounded well over 10 years (NUVL: +456. 1%, RVMD: +422. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RVMD and NUVL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.